CompletedPhase 4

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

China48 participantsStarted 2022-04-14

Plain-language summary

The purpose of this study is to illustrate pharmacokinetics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in patients during laparoscopic surgery

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ASA: Ⅰ\~Ⅲ
✓. BMI≥25kg/m²
✓. Patients receiving bariatric surgery.

Exclusion criteria

✕. Pregnant or lactating women
✕. Neuromuscular diseases
✕. Malignant hyperthermia or allergic history during general anesthesia
✕. Drugs that react with rocuronium and vecuronium were taken

What they're measuring

Plasma Concentration of Sugammadex

Timeframe: 0, 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours

TOF ratio of Recovery Time

Timeframe: TOF ratio at 30, 60, 90, 120, 150 seconds after administration

Trial details

NCT IDNCT05328778

SponsorGuangzhou General Hospital of Guangzhou Military Command

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-01

View on ClinicalTrials.gov More Pharmacokinetics trials